Item no. |
PTM-6514 |
Manufacturer |
PTM Biolabs
|
Amount |
100 ul |
Category |
|
Type |
Antibody Monoclonal |
Format |
Lyophilized powder |
Applications |
WB, FC, ICC, IHC-P |
Clone |
JRMR-10941-48 |
Specific against |
Human (Homo sapiens) |
Host |
Rabbit |
Isotype |
IgG |
Conjugate/Tag |
Unconjugated |
ECLASS 10.1 |
42030590 |
ECLASS 11.0 |
42030590 |
UNSPSC |
12352203 |
Alias |
mATG9, APG9-like 1, APG9L1 |
Shipping condition |
Room temperature |
Available |
|
Manufacturer - Type |
Primary Antibodies |
Manufacturer - Applications |
WB, IHC-P, ICC/IF, FC |
Manufacturer - Category |
Organelle Marker Antibodies |
Manufacturer - Targets |
ATG9A |
Shipping Temperature |
Ambient temperature |
Storage Conditions |
Store at -20°C. Avoid freeze/thaw cycles. |
Stability |
Stable for 12 months from date of receipt/reconstitution. |
Manufacturer - Research Area |
Cell Biology, Neuroscience, Cancer, Cardiovascular Biology, Metabolism |
Product description |
ATG9A are lipid scramblases that play a role in autophagosome expansion. ATG9A is present in numerous intracellular compartments, including the trans-Golgi network and early and recycling endosomes, and traffics through the secretory pathway to the plasma membrane and to the endocytic pathway from the plasma membrane. ATG9A protects cells against plasma membrane damage caused by a spectrum of exogenous and endogenous agents, including permeabilization by gasdermin and mixed lineage kinase domain like (MLKL), which generate pores at the plasma membrane or perturb plasma membrane integrity, respectively, during programmed cell death processes of pyroptosis and necroptosis. We furthermore define the ATG9A–IQGAP1 apparatus that integrates with the ESCRT system to cooperatively heal areas of plasma membrane damage. |
Purification Method |
Protein A purified |
Formula |
PBS, Glycerol, BSA |
PTM |
Unmodified |
Clonality |
Recombinant Monoclonal |
Background |
ATG9A are lipid scramblases that play a role in autophagosome expansion. ATG9A is present in numerous intracellular compartments, including the trans-Golgi network and early and recycling endosomes, and traffics through the secretory pathway to the plasma membrane and to the endocytic pathway from the plasma membrane. ATG9A protects cells against plasma membrane damage caused by a spectrum of exogenous and endogenous agents, including permeabilization by gasdermin and mixed lineage kinase domain like (MLKL), which generate pores at the plasma membrane or perturb plasma membrane integrity, respectively, during programmed cell death processes of pyroptosis and necroptosis. We furthermore define the ATG9A–IQGAP1 apparatus that integrates with the ESCRT system to cooperatively heal areas of plasma membrane damage. |
Cellular Localization |
Endoplasmic reticulum, Golgi apparatus, Endosome |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.